Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
OptiTROP-Lung04
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
- NCT05870319 ↗
- Active, not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Deep
We haven't built an HCP commentary report on OptiTROP-Lung04 (SKB264, pemetrexed and 2 more in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OptiTROP-Lung04 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| Bluesky threads | 5 | |
| Podcasts | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SKB264; Pemetrexed; Carboplatin; Cisplatin
- Arms
- SKB264 by IV infusion on Days 1 and 15 of each 4-week cycle; · Experimental
- pemetrexed+ carboplatin or on Day 1 of each 3-week cycle, with 4 cycles chemo · Active comparator
- Enrollment
- 376
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Jun 26, 2023
- Primary completion
- Jul 11, 2024
- Results posted
- No
- Registry record
- NCT05870319 · updated May 8, 2026
Publications
linked from the registry- Fang W, Wu L, Meng X, Yao Y, Zuo W, Yao W, Xie Y, Zhang Y, Cui J, Zhang Y, Li X, Zhuang W, Fang J, Wang Q, Jiang W, Li K, Bai Y, Luo Y, Ma F, Yu Y, Zheng W, Liu Z, Yang B, Ma R, Fang Y, Yang R, Jiang L, Hu J, Yang J, Diao Y, Jin X, Ge J, Yang Y, Zhang L. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2026 Jan 1;394(1):13-26. doi: 10.1056/NEJMoa2512071. Epub 2025 Oct 19. PubMed 41124220